[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44

Advertisement
4. Endo K, Kohnoe S, Toh Y, Haraguchi M, Nishiyama K, Okamura T, Baba H, Maehara Y: A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin. J Exp Clin Cancer Res; 2005 Dec;24(4):647-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal small cell carcinoma with multiple liver metastases responding to chemotherapy with irinotecan plus cisplatin.
  • We report a case of small cell esophageal carcinoma (SCEC) with multiple liver metastases treated with some success by chemotherapy with irinotecan (CPT-11) plus cisplatin (CDDP).
  • Radiologic and endoscopic examination of a 75-year-old man with multiple liver tumors disclosed a 4.0-cm type 2 tumor in the middle third of the esophagus.
  • An endoscopically obtained biopsy specimen was diagnosed as undifferentiated small cell carcinoma.
  • Multiple liver metastases were confirmed but lymph node metastases and distant metastases other than those in the liver were not detected.
  • After six courses of chemotherapy with CPT-11 plus CDDP, the primary lesion showed complete response and liver metastases showed partial response.
  • However, because all lesions almost immediately relapsed or progressed, arterial infusion chemotherapy for liver metastases and radiation for the primary lesion were given as second-line treatment.
  • The primary lesion showed complete response with radiation.
  • Arterial infusion chemotherapy prevented the progression of liver metastases once, but the patient died of liver failure at last.
  • No distant lesions including metastatic lymph nodes were confirmed over the course of his illness, and the patient survived for a year after first diagnosis.
  • Although the prognosis of SCEC is quite unfavorable due to highly aggressive behavior, a better prognosis is possible with effective chemotherapy and second-line treatment is important in improving prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Cisplatin / therapeutic use. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471329.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. De Simone P, Coletti L, Campani D, Falcone A, Filipponi F: Liver transplantation for metastatic sinonasal undifferentiated carcinoma: a case report. Transplant Proc; 2008 Dec;40(10):3821-2
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for metastatic sinonasal undifferentiated carcinoma: a case report.
  • Sinonasal undifferentiated carcinoma (SNUC) is a relatively newly described malignancy of the nasal cavity and paranasal sinuses with a reported 25% to 30% risk for distant metastases.
  • We have reported herein the case of a patient who underwent orthotopic liver transplantation (OLT) for hepatic metastases of SNUC.
  • Despite the limited follow-up, the present case suggests that a long disease-free survival after primary surgery, absence of local-regional recurrence, and stability of disease after chemotherapy may represent selection criteria to refer patients for OLT.
  • However, continued follow-up and larger series are necessary to test this hypothesis in the long-term and to assess the role of posttransplantation chemotherapy.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Liver Transplantation. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Metastasis / therapy. Tomography, X-Ray Computed. Treatment Outcome


6. Fandi A, Bachouchi M, Azli N, Taamma A, Boussen H, Wibault P, Eschwege F, Armand JP, Simon J, Cvitkovic E: Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol; 2000 Mar;18(6):1324-30
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.
  • PURPOSE: To review incidence and analyze profile of long-term complete responders among patients with undifferentiated carcinoma of nasopharyngeal type (UCNT) treated at a single institution.
  • PATIENTS AND METHODS: We present a cohort of 20 long-term unmaintained complete responders to chemotherapy for metastatic UCNT treated at the Institut Gustave Roussy between April 1978 and November 1996.
  • A patient was considered a long-term survivor if he or she was disease-free for more than 36 months without treatment after obtaining a complete response by chemotherapy.
  • Of 16 pretreated patients, 11 were pretreated by radiotherapy alone and five by chemotherapy and radiotherapy.
  • Tumor sites were bone in 15 patients, lung in four, and liver (biopsy-proven) in two.
  • Chemotherapy included the following: cisplatin, bleomycin, and fluorouracil in five patients; bleomycin, epirubicin, and cisplatin in seven patients; fluorouracil, mitomycin, epirubicin, and cisplatin in four patients; and fluorouracil, bleomycin, epirubicin, and cisplatin in one patient.
  • RESULTS: As of June 1999, 14 of 20 patients were still alive with no evidence of disease after treatment (disease-free survival time, 82+ to 190+ months), three patients died of other causes while in complete response at 61, 109, and 208 months after treatment, and three patients died of disease at 42, 89, and 115 months after treatment.
  • CONCLUSION: Our data support a curative role for chemotherapy in metastatic UCNT and are a major incentive to continue research for better combinations to increase the percentage of patients with metastatic UCNT who attain complete responses and long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Nasopharyngeal Neoplasms / drug therapy. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715304.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Takahashi H, Yasuda A, Ochi N, Sakamoto M, Takayama S, Wakasugi T, Funahashi H, Sawai H, Satoh M, Akamo Y, Takeyama H: Granulocyte-colony stimulating factor producing rectal cancer. World J Surg Oncol; 2008;6:70
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some hepatic tumors in the liver were revealed concurrently, and their appearance suggested multiple liver metastases.
  • Low anterior resection was performed. with the help of histopathological examination and immunohistochemical studies, we diagnosed this case to be an undifferentiated carcinoma of the rectum.
  • Modified-FOLFOX6 therapy was initiated to treat the liver metastases, but there was no effect, and peritoneal dissemination had also occurred.
  • The patient died from rapid growth of the liver metastases and peritoneal dissemination 2 months after surgery.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Carcinoma / secondary. Colectomy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Peritoneal Neoplasms / secondary. Prognosis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 1999 Oct;34(5):640-4 [10535496.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):105-15 [11121868.001]
  • [Cites] J Urol. 2002 May;167(5):2130 [11956459.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):1058-61 [12359263.001]
  • [Cites] Jpn J Clin Oncol. 1985 Jun;15(2):431-41 [2410641.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3700-2 [8033086.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2102-11 [9610689.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2173-83 [9610697.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):378-85 [9663599.001]
  • [Cites] Postgrad Med J. 2005 May;81(955):333-7 [15879049.001]
  • [Cites] Surg Today. 2005;35(7):590-3 [15976958.001]
  • [Cites] Surg Today. 2006;36(1):63-7 [16378196.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):246-9 [16850133.001]
  • [Cites] Clin Chim Acta. 2006 Sep;371(1-2):143-7 [16603145.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):308-10 [17184692.001]
  • [Cites] Liver Int. 2007 Jun;27(5):716-21 [17498259.001]
  • [Cites] Jpn J Clin Oncol. 2007 Oct;37(10):793-6 [17720735.001]
  • (PMID = 18588705.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Other-IDs] NLM/ PMC2474610
  •  go-up   go-down


8. Tao Y, Bidault F, Bosq J, Bourhis J: Distant metastasis of undifferentiated carcinoma of nasopharyngeal type. Onkologie; 2008 Nov;31(11):574-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of undifferentiated carcinoma of nasopharyngeal type.
  • [MeSH-major] Anesthetics, Combined / administration & dosage. Carcinoma / secondary. Carcinoma / therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Nasopharyngeal Neoplasms / secondary. Nasopharyngeal Neoplasms / therapy

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2008 Nov;31(11):635-6 [19145100.001]
  • (PMID = 19145087.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anesthetics, Combined
  •  go-up   go-down


9. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature.
  • The patient underwent partial jejunectomy and biopsy of a liver metastasis.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • In summary, we report the exceptional case of an undifferentiated carcinoma of the jejunum with rhabdoid phenotype.
  • [MeSH-major] Carcinoma / pathology. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


10. Thurnher D, Kletzmayr J, Formanek M, Quint C, Czerny C, Burian M, Kornek G: Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology; 2001;61(2):143-6
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx.
  • OBJECTIVE: A cisplatin-containing regimen followed by radiation therapy is the recommended treatment for patients with advanced nasopharyngeal carcinoma.
  • We report a case of a 58-year-old woman with hemolytic-uremic syndrome (HUS) who received induction chemotherapy for undifferentiated squamous cell carcinoma of the nasopharynx.
  • PATIENTS AND METHODS: During the 2nd course of chemotherapy (consisting of bleomycin, cisplatin and epirubicin), the patient developed hemolytic anemia, thrombocytopenia, and acute renal failure.
  • RESULTS: Twice daily therapeutic plasma exchange (TPE) with fresh-frozen plasma, hemodialysis and high-dose cortisone was performed.
  • Six weeks after the administration of the second course of chemotherapy, the patient had fully recovered from HUS, and radiation therapy was carried out as planned.
  • The patient responded well to treatment, but died 9 months after the diagnosis due to liver metastases.
  • CONCLUSION: We demonstrated that early TPE with fresh-frozen plasma and high-dose cortisone is a potentially successful treatment modality for the usually fatal, fulminant form of chemotherapy-induced HUS.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cisplatin / adverse effects. Hemolytic-Uremic Syndrome / chemically induced. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Cortisone / therapeutic use. Epirubicin / administration & dosage. Fatal Outcome. Female. Humans. Middle Aged. Plasma. Plasma Exchange. Renal Dialysis

  • Genetic Alliance. consumer health - Hemolytic uremic syndrome.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11528253.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; V27W9254FZ / Cortisone
  •  go-up   go-down


11. Kanoh T, Ohnishi T, Tono T, Takemoto H, Shiozaki K, Kimura Y, Iwazawa T, Nakano Y, Yano H, Monden T: [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1953-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
  • Sigmoidectomy was performed for a 69-year-old man with sigmoid colon cancer and unresectable multiple liver metastases.
  • The histological diagnosis was undifferentiated carcinoma of sigmoid colon.
  • Hepatic arterial infusion chemotherapy with 5 FU and systemic chemotherapy with CPT-11 were performed after the operation.
  • A complete response (CR) was achieved for liver metastases.
  • This combination therapy is expected to be an alternative treatment of colorectal cancer with unresectable multiple liver metastases.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212157.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Thongprasert S, Cheewakriangkrai R, Napapan S: Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. J Med Assoc Thai; 2002 Dec;85(12):1296-300
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
  • The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC).
  • Of 28 evaluable cases, 18 were adenocarcinoma, 3 squamous cell, 3 large cell and 4 undifferentiated carcinoma.
  • Five cases (19.2%) had liver metastases, 3 (11.5%) brain metastases, 6 (23%) bone metastases, and 17 (65.3%) metastatic nodules in the lung.
  • Besides chemotherapy, seven cases had received prior thoracic irradiation and two whole brain irradiation.
  • Two cases had prior surgery for malignant pleural effusion and one had thoracotomy for the resection of the primary tumor.
  • The time from the last dose of chemotherapy to the start of this study was less than 6 months in 20 cases, 6-12 months in 9, 12-24 months in 3 and more than 24 months in 2 cases.
  • One patient with initial small cell lung cancer had developed NSCLC before entering this study.
  • The median survival time was 23.8 weeks.
  • Docetaxel should be considered as second line chemotherapy in advanced NSCLC when primary chemotherapy including cisplatin and/or paclitaxel had failed.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Palliative Care / methods. Taxoids
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12678167.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen ().
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • In asynchronous cases, being aware of this association can explain the absence of a second primary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Takeuchi S, Nakayama A, Ishida S, Suzuki M, Katsuragi A, Adachi M: [A case of huge submandibular malignant tumor treated successfully with UFT chemotherapy]. Gan To Kagaku Ryoho; 2004 Feb;31(2):219-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of huge submandibular malignant tumor treated successfully with UFT chemotherapy].
  • We report a patient with a huge submandibular malignant tumor showing an excellent response to chemotherapy with UFT.
  • Fine needle aspiration cytology of the mass indicated undifferentiated malignant tumor.
  • Oral UFT was discontinued due to liver dysfunction.
  • There has been no evidence of recurrence for 5 years after discontinuation of chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Submandibular Gland Neoplasms / drug therapy. Tegafur / administration & dosage. Uracil / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14997755.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


15. Scherwitz P, Lindenfelser R, Krüger I: [Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma]. Chirurg; 2002 Aug;73(8):859-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
  • We present a case of a 67-year-old female patient with liver metastasis of SCC.
  • Initially, the primary tumor was not found and the patient underwent chemotherapy.
  • Microscopic examination revealed that the adenocarcinoma was combined with an undifferentiated carcinomatous component.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / secondary. Colonic Neoplasms / diagnosis. Liver Neoplasms / secondary. Neoplasms, Multiple Primary. Neoplasms, Unknown Primary. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Colectomy. Colon / pathology. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Immunohistochemistry. Liver / pathology. Time Factors. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12425166.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Lau JS, Yeo W, Chan YL, Chan W, Hui P, Leung SF, Kwan WK, Chan AT: Intracranial metastasis from nasopharyngeal carcinoma: Report of three cases and review of literature. J Clin Oncol; 2004 Jul 15;22(14_suppl):5608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastasis from nasopharyngeal carcinoma: Report of three cases and review of literature.
  • : 5608 Background: Brain metastasis (mets) from nasopharyngeal carcinoma (NPC) is a controversial entity.
  • All 3 patients received whole brain radiation therapy (WBRT) for the brain mets.
  • Static disease was achieved with chemotherapy.
  • Histology of the lesion revealed metastatic undifferentiated carcinoma, staining positive for Epstein-Barr virus-encoded RNA (EBER).
  • He received WBRT and remained alive at the most recent follow-up, which was 1 year after the diagnosis of brain mets.
  • At 32 months follow-up he was found to have mets in the lungs, liver and bone.
  • Partial response was achieved with chemotherapy.
  • Biopsy confirmed undifferentiated carcinoma consistent with mets of NPC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015287.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ho CL, Lee SH, Chen LM, Chao TY: Epstein-Barr virus early ribonucleic acids as a diagnostic adjunct for relapsed metastatic tumors in patients with cured primary undifferentiated nasopharyngeal carcinoma. Am J Otolaryngol; 2000 Mar-Apr;21(2):80-4
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus early ribonucleic acids as a diagnostic adjunct for relapsed metastatic tumors in patients with cured primary undifferentiated nasopharyngeal carcinoma.
  • PURPOSE: Epstein-Barr virus (EBV) has been consistently shown to be associated with undifferentiated nasopharyngeal carcinoma (NPC).
  • In this article, the authors attempt to detect Epstein-Barr virus in distant relapsed metastatic sites in undifferentiated NPC patients with cured primary cancer.
  • We used a nonisotopical ISH technique to examine the presence of EBERs in paraffin-embedded tissues obtained from 1 paired specimen of primary NPC and its metastatic counterpart at liver and 2 metastatic specimens of retroperitoneal lymph nodes and bone.
  • RESULTS: All the primary lesions and the metastatic tumors of NPC with undifferentiated histology contained EBERs that could be clearly detected in the nuclei of cancer cells.
  • These results suggest that this nonisotopical ISH method of EBERs can be potentially used to diagnose NPC patients developing distant relapsed metastatic lesions with cured primary cancer early.
  • It can offer quick information as to institute suitable salvage chemotherapy for these patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Carcinoma / secondary. Herpesvirus 4, Human / isolation & purification. Nasopharyngeal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / virology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Bone Neoplasms / virology. Female. Humans. In Situ Hybridization. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Liver Neoplasms / virology. Lymphatic Metastasis. Male. RNA, Viral / analysis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758991.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Viral
  •  go-up   go-down


18. Cheng JC, Esparza SD, Knez VM, Sakamoto KM, Moore TB: Severe lactic acidosis in a 14-year-old female with metastatic undifferentiated carcinoma of unknown primary. J Pediatr Hematol Oncol; 2004 Nov;26(11):780-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe lactic acidosis in a 14-year-old female with metastatic undifferentiated carcinoma of unknown primary.
  • The diagnosis of an undifferentiated carcinoma of unknown primary was made after open breast biopsy of the mass with negative immunohistochemical studies for breast malignancies.
  • Further evaluation showed extensive metastatic disease affecting the bone marrow, ribs, liver, and brain with magnetic resonance imaging evidence of carcinomatous meningitis.
  • Despite 2 months of chemotherapy and intensive supportive care, the patient died of severe lactic acidosis and disseminated intravascular coagulation after exaggerated menstrual bleeding.
  • The association of severe lactic acidosis and undifferentiated carcinoma of unknown primary in an adolescent has not been previously described.
  • [MeSH-major] Acidosis, Lactic / etiology. Carcinoma / complications. Carcinoma / pathology
  • [MeSH-minor] Adolescent. Breast Neoplasms / pathology. Disseminated Intravascular Coagulation / etiology. Fatal Outcome. Female. Hemorrhage / etiology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15543020.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Foltys D, Linkermann A, Heumann A, Hoppe-Lotichius M, Heise M, Schad A, Schneider J, Bender K, Schmid M, Mauer D, Peixoto N, Otto G: Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report. Transplant Proc; 2009 Jul-Aug;41(6):2639-42
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.
  • Undifferentiated neuroendocrine small-cell carcinoma is an aggressive tumor with the tendency to spread.
  • The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound.
  • After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.
  • Despite chemotherapy the patient died 7 months after orthotopic liver transplantation (OLT).
  • All involved transplantation centers were informed immediately following diagnosis.
  • One year after transplantation, liver metastases caused by a histologically proven small-cell carcinoma from the same donor were apparent.
  • Chemotherapy was immediately started and the graft was removed.
  • Despite continued treatment the tumor progressed and the patient died after repeated intestinal complications.
  • CONCLUSION: Therapeutic regimens in recipients suffering from donor-derived carcinoma differ depending on the transplanted organ.
  • Graft removal of non-life-sustaining organs and discontinuation of immunosuppressive medication should result in complete tumor rejection.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Carcinoma, Small Cell / pathology. Embolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Transplantation / methods. Tissue Donors. alpha 1-Antitrypsin Deficiency / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. DNA Fingerprinting. Etoposide / therapeutic use. Heart Transplantation / immunology. Heart Transplantation / pathology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Transplantation / immunology. Kidney Transplantation / pathology. Male. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Nephrectomy


20. Schuette K, Folprecht G, Kretzschmar A, Link H, Koehne CH, Gruenwald V, Stahl M, Huebner G: Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie; 2009 Apr;32(4):162-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
  • BACKGROUND: Carcinomas of unknown primary (CUP) account for approximately 2-5% of all cancer diagnoses.
  • Except for some subsets with favorable prognosis, for most of these patients treatment options are limited, and no standard first-line regimen has been identified.
  • We performed a phase II study with oxaliplatin (OX) and capecitabine (CAP) as first-line treatment for patients with histo-or cytologically proven adeno- or undifferentiated CUP.
  • PATIENTS AND METHODS: Protocol treatment in this multicenter trial consisted of CAP 1,000 mg/m(2) twice daily orally (days 1-14) and OX 130 mg/m(2) intravenously (day 1), repeated every 21 days at a maximum of 6 cycles.
  • The primary endpoint was the response rate (RR).
  • RESULTS: 51 patients with CUP (71% with poorly differentiated adenocarcinoma; 41% ECOG performance status (PS) 0, 39% PS 1, 10% PS 2, 55% with elevated lactate dehydrogenase (LDH), and 39% with liver metastases) were enrolled in this study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Neoplasms, Unknown Primary / drug therapy. Organoplatinum Compounds / administration & dosage
  • [MeSH-minor] Adult. Aged. Capecitabine. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Apr;32(4):159-60 [19372709.001]
  • (PMID = 19372710.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Nagahama T, Maruyama M, Tokairin Y, Yoshida T, Baba H, Kure N, Ebuchi M: [A patient with small-cell carcinoma of the esophagus with synchronous liver metastasis surviving 48 months after surgery]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1655-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with small-cell carcinoma of the esophagus with synchronous liver metastasis surviving 48 months after surgery].
  • Small-cell carcinoma of the esophagus is regarded as having a poor prognosis with frequent and early systemic metastasis.
  • Recently, several reports have described small-cell carcinoma satisfactorily treated by chemotherapy and radiation therapy combined with surgery.
  • We herein report a patient with small-cell carcinoma of esophagus with synchronous multiple liver metastasis who survived 44 months after surgery.
  • A biopsy specimen of the lower esophagus demonstrated undifferentiated carcinoma of the esophagus.
  • Ultrasonographic investigation demonstrated solitary SOL in the liver.
  • As ultrasonographic evaluation during laparotomy revealed multiple liver metastases, a hepatic artery infusion catheter was inserted into the proper hepatic artery.
  • A pathological study of the resected esophagus and a biopsy specimen of the liver revealed undifferentiated cell carcinoma of the esophagus (small-cell type).
  • During hospitalization, hepatic artery infusion therapy (CDDP 20 mg/4 h and 5-FU 750 mg/5 h) was given for 4 days starting on days 14 and 28.
  • After chemotherapy, liver metastasis could not be detected by ultrasonographic investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / secondary. Esophageal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11708001.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  • [Number-of-references] 9
  •  go-up   go-down


22. Xiao E, Hu G, Liu P, Hu D, Liu S, Hao C: The effect of different interventional treatment on P-Glycoprotein in different histopathological types and grades of primary hepatocellular carcinoma. J Tongji Med Univ; 2000;20(3):231-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of different interventional treatment on P-Glycoprotein in different histopathological types and grades of primary hepatocellular carcinoma.
  • To study the effect of the different interventional treatment on P-Glycoprotein (Pgp) in different histopathological types of primary hepatocellular carcinoma (PHC), 98 surgically and histologically verified PHC specimens were obtained.
  • The patients included 57 patients treated by surgical resection alone and 41 patients receiving second-stage surgical resection after four kinds of interventional treatment.
  • The positive rate of Pgp was 100% in group of chemotherapy alone (P < 0.05), 62.5% in group of chemotherapy combined with iodized oil (P > 0.05), 46.6% in group of chemotherapy combined with iodized oil and spongia gelatini absorbens (Sga) (P > 0.05), 18.18% in group of chemotherapy combined with Ethanol-iodized-oil and Sga (P < 0.05) and 52.63% in group of surgical resection alone.
  • The positive rate of Pgp varied with different histopathological types, with rate of clear cell PHC being the lowest, and that of poorly differentiated or undifferentiated PHC the highest.
  • Overexpression of Pgp may be responsible for the intrinsic and acquired drug resistance of PHC.
  • Multidrug resistance (MDR) varied with different histological types.
  • Therapy of PHC should be tailored according to individual.
  • Local chemotherapy combined with ethanol-iodized-oil and Sga embolization may become a new way to overcome MDR of PHC.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / therapy. P-Glycoprotein / metabolism
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Radiography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11215058.001).
  • [ISSN] 0257-716X
  • [Journal-full-title] Journal of Tongji Medical University = Tong ji yi ke da xue xue bao
  • [ISO-abbreviation] J. Tongji Med. Univ.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


23. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S: Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas; 2005 Jul;31(1):69-73
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting recurrence after resection of pancreatic ductal carcinoma.
  • OBJECTIVE: Pancreatic ductal carcinoma frequently recurs postoperatively, and we analyzed clinicopathological features of patients treated by surgical resection to find predictors of postoperative recurrence.
  • RESULTS: Mean survival time and actuarial 5-year disease-specific survival were significantly lower in cases of hepatic metastasis (13 months, 0%) and in cases of peritoneal carcinomatosis (15 months, 6.8%) than in cases of local retroperitoneal recurrence (30 months, 21%).
  • Univariate and logistic regression analyses showed undifferentiated adenocarcinoma to be independently associated with hepatic metastasis (odds ratio, 7.4; 95% confidence interval, 1.5-37.0) and invasion of the portal vein to be independently associated with peritoneal carcinomatosis (odds ratio, 4.0; 95% confidence interval, 1.2-12.8).
  • Multivariate analysis showed undifferentiated adenocarcinoma, invasion of the anterior capsule, and invasion of the portal vein to be independent prognostic factors.
  • CONCLUSION: Undifferentiated adenocarcinoma and invasion of the portal vein are predictors of poor outcome and are related to hepatic metastasis and peritoneal carcinomatosis, respectively.
  • Postoperative adjuvant chemotherapy, including intra-arterial chemotherapy, should be selected according to prediction of the patterns of recurrence.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Neoplasm Recurrence, Local / etiology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Portal Vein / pathology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968250.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eight cases of neuroendcrine carcinoma of the head and neck].
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • We reported eight cases of stage IV small cell neuroendocrine carcinoma of the head and neck, all in men with a mean onset age of 62 years (range: 45 to 80 years).
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Five patients died of distant metastasis to the brain, bone, lung, liver, or skin within 12 months.
  • One is alive with liver metastasis.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


25. Luk NM, Yu KH, Choi CL, Yeung WK: Skin metastasis from nasopharyngeal carcinoma in four Chinese patients. Clin Exp Dermatol; 2004 Jan;29(1):28-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastasis from nasopharyngeal carcinoma in four Chinese patients.
  • Nasopharyngeal carcinoma (NPC) is a common malignancy among southern Chinese.
  • The tumours are mostly undifferentiated carcinomas and are associated with Epstein-Barr virus.
  • Radiotherapy with or without chemotherapy is the standard treatment.
  • Though metastatic lung, bone or liver disease is not uncommon on relapse, skin metastasis is rarely reported.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723715.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Malogolowkin MH, Stanley P, Steele DA, Ortega JA: Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol; 2000 Mar;18(6):1279-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and toxicity of chemoembolization for children with liver tumors.
  • PURPOSE: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver.
  • PATIENTS AND METHODS: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression.
  • All but one newly diagnosed patient with HCC had previously received systemic chemotherapy.
  • Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE.
  • CONCLUSION: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children.
  • [MeSH-major] Chemoembolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / therapy. Child. Child, Preschool. Collagen / administration & dosage. Collagen / therapeutic use. Feasibility Studies. Female. Hepatic Artery. Hepatoblastoma / therapy. Humans. Infant. Male. Sarcoma / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10715298.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 121938-23-6 / Angiostat; 9007-34-5 / Collagen
  •  go-up   go-down


27. Rosito P, Mancini AF, Semeraro M, Paone G, Lima M, Federici S, Domini M, Burnelli R, Baroncini S, Gentili A, Paolucci G, Domini R: [Malignant primary tumors of the liver in childhood]. Pediatr Med Chir; 2002 May-Jun;24(3):200-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary tumors of the liver in childhood].
  • Twenty-one children (16 males, 5 females) with malignant primary hepatic tumors were admitted to the Pediatric Clinic of the University of Bologna between June 1973 and July 2001.
  • The diagnosis was hepatoblastoma (HBL) in 16 cases; hepatocellular carcinoma (HCA) in 3 cases; undifferentiated sarcoma in 1, malignant rhabdoid tumour of the liver in 1.
  • Median age at diagnosis was 1.8 year (1 mounth-13 years).
  • At diagnosis 3 pts presented lung metastases.
  • In 10 patients, initially with unresesectable tumor, chemotherapy was started first.
  • Drugs used were mostly Cisplatinum or Carboplatinum with Doxorubicin.
  • We conclude that excluding metastases at diagnosis (3 deaths), the main prognostic factor is resectability and radical surgery: in our experience 4 patients with unresectable tumor died, as 2 patients with microscopical residual after surgery.
  • [MeSH-major] Liver Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12236033.001).
  • [ISSN] 0391-5387
  • [Journal-full-title] La Pediatria medica e chirurgica : Medical and surgical pediatrics
  • [ISO-abbreviation] Pediatr Med Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Almogy G, Lieberman S, Gips M, Pappo O, Edden Y, Jurim O, Simon Slasky B, Uzieli B, Eid A: Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol; 2004 May;30(4):421-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre.
  • BACKGROUND: Primary hepatic sarcoma is a rare tumour with a poor prognosis.
  • METHODS: From 1997 to 2002 eight patients had liver resection for primary sarcoma of the liver at our institution.
  • The clinical characteristics, imaging findings, surgical procedures, adjuvant therapy and outcome were retrospectively reviewed.
  • There were two patients each with angiosarcoma (AS), leiomyosarcoma (LMS), and undifferentiated embryonal sarcoma (UES), one patient with epithelioid hemangioendothelioma (EHE) and one patient with malignant peripheral nerve sheath sarcoma (PNSS).
  • Preoperative diagnosis of a primary liver sarcoma was made in 7/8 cases, either by fine needle aspiration (n = 5) or angiography (n = 2).
  • Two patients developed complications and there was one death.
  • Systemic chemotherapy led to tumour regression in both patients with UES which enabled a second hepatic resection.
  • CONCLUSIONS: The majority of patients with primary liver sarcoma present with right upper quadrant pain, fever and a liver mass.
  • Differentiating the rare primary liver sarcoma from the much more common hepatocellular carcinoma (HCC) may aid in planning therapy.
  • Liver resection combined with adjuvant chemotherapy are the mainstays of treatment for UES in the adult.
  • [MeSH-major] Liver Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Hepatectomy / methods. Humans. Length of Stay. Liver Function Tests. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15063896.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Wada Y, Yamamoto T, Kita Y, Fukunishi S, Ashida K: [An autopsy case of encephalopathy associated with small cell carcinoma of the stomach with nonconvulsive status epilepticus resembling Creutzfeldt-Jakob disease]. No To Shinkei; 2003 May;55(5):423-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsy case of encephalopathy associated with small cell carcinoma of the stomach with nonconvulsive status epilepticus resembling Creutzfeldt-Jakob disease].
  • A 64-year-old man developed progressive dementia and altered consciousness with myoclonus over 2 months.
  • Since his consciousness level fluctuated and the PSD were spiky, we came to a diagnosis of nonconvulsive status epilepticus (NCSE).
  • Biopsy of the periaortic lymph node by laparotomy revealed undifferentiated adenocarcinoma with its origin being unclear.
  • Chemotherapy didn't work well for the tumor and the patient underwent a downhill course, although his mental and neurological manifestation were mostly unremarkable.
  • Autopsy confirmed small cell carcinoma originating in the stomach and metastases in the liver and lungs.
  • [MeSH-major] Brain Diseases / pathology. Carcinoma, Small Cell / complications. Creutzfeldt-Jakob Syndrome / diagnosis. Status Epilepticus / diagnosis. Stomach Neoplasms / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Electroencephalography. Humans. Male


30. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol; 2000 Sep;18(17):3101-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
  • PURPOSE: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP).
  • Treatment courses were repeated every 3 weeks to a maximum of eight cycles.
  • Forty-seven patients had adenocarcinomas, 27 had undifferentiated carcinomas, and three had squamous cell carcinomas.
  • Thirty-three patients presented with liver, bone, or multiple organ metastases, 23 with predominantly nodal/pleural disease, and 19 (16 women) with peritoneal carcinomatosis.
  • There were no differences in response between adenocarcinomas and undifferentiated carcinomas, but efficacy varied among clinical subsets.
  • The response rates and median survival times in the three clinically defined subsets were 47.8% and 13 months, respectively, for patients with predominantly nodal/pleural disease, 68.4% and 15 months, respectively, in women with peritoneal carcinomatosis, and 15.1% and 10 months, respectively, in patients with visceral or disseminated metastases.
  • Chemotherapy was well-tolerated.
  • CONCLUSION: Carboplatin plus paclitaxel combination chemotherapy is effective in patients with predominantly nodal/pleural metastases of unknown primary carcinoma and in women with peritoneal carcinomatosis.
  • However, in patients with liver, bone, or multiple organ involvement, the combination offers limited benefit.
  • The investigation of novel treatment approaches is highly warranted for this group of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adult. Aged. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Drug Administration Routes. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10963638.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Szumera M, Czauderna P, Popadiuk S, Gołebiewski J, Sznurkowska K, Renke J, Korzon M: [Assessment of treatment results in children with malignant liver tumours in own experience]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):539-49
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of treatment results in children with malignant liver tumours in own experience].
  • AIM: The assessment of malignant liver tumours in children treated in our centre between years 1985-2004 has been made in order to analyze the prognostic factors and improvement in survival rate.
  • MATERIAL AND METHODS: 17 patients with malignant liver tumours were followed-up.
  • There were 10 (58,8%) patients with hepatoblastomas, 5 (29,4%) hepatocarcinomas, 1 (5,9%) undifferentiated embryonal sarcoma and 1 (5,9%) rhabdomyosarcoma.
  • Primary metastatic disease was recognized in 3 cases as: hepatic vascular involvement, lungs, femoral bone and lymph nodes of liver hilus metastases.
  • All patients underwent preoperative chemotherapy.
  • Secondary metastases appeared in lungs, lymph nodes of liver hilus and central nervous system in 4 cases.
  • RESULTS: Twelve patients are alive with median follow-up 34,0 mths, five died with median survival time 16,0 mths.
  • Total excision of liver tumour had no statistical significance in lifetime prolongation (p =0,12).
  • CONCLUSIONS: Complete surgical excision had no statistical significance in increasing survival time in liver tumour patients.
  • Metastatic disease had statistical significance in shortening overall survival of patients with liver tumours.
  • Unsatisfactory results in hepatocarcinoma treatment in children dramatically demonstrate the need for new treatment approaches.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Hepatocellular. Child. Child, Preschool. Female. Follow-Up Studies. Hepatoblastoma / pathology. Hepatoblastoma / secondary. Hepatoblastoma / therapy. Humans. Infant. Male. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / therapy. Oncology Service, Hospital / statistics & numerical data. Poland. Retrospective Studies. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719167.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


32. Hu Y, Lu T, Mai W, Han F, Huang Y, Liu H, Zhang E: [Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec;36(6):463-7
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy].
  • OBJECTIVE: To evaluate the long-term outcome and prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma (NPC) after initial radiation therapy.
  • METHODS: From January 1985 to December 1986, 100 patients (71 male, 29 female) with the diagnosis of NPC were found to have skull base erosion from computed tomography (CT).
  • Ninety-six patients had World Health Organization (WHO) type III undifferentiated carcinoma while four had type I carcinomas.
  • Metastatic workup including chest radiography, liver ultrasound and liver function test were negative.
  • All patients underwent external beam radiotherapy alone to 66-80 Gy over 6-8 weeks.
  • Daily fraction size of 2 Gy was delivered utilizing cobalt-60 or linear accelerator.
  • No patient received chemotherapy.
  • CONCLUSION: This report presents one of the longest follow-ups of patients with nasopharyngeal carcinoma invading skill base.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Nasopharyngeal Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12761966.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Haberkorn U, Altmann A, Jiang S, Morr I, Mahmut M, Eisenhut M: Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med; 2001 May;28(5):633-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene.
  • Human thyroperoxidase (hTPO) is critical for the accumulation of iodide in thyroid tissues.
  • Poorly differentiated and anaplastic thyroid tumours which lack thyroid-specific gene expression fail to accumulate iodide and, therefore, do not respond to iodine-131 therapy.
  • We consequently investigated whether transfer of the hTPO gene is sufficient to restore the iodide-trapping capacity in undifferentiated thyroid and non-thyroid tumour cells.
  • The human anaplastic thyroid carcinoma cell lines C643 and SW1736, the rat Morris hepatoma cell line MH3924A and the rat papillary thyroid carcinoma cell line L2 were used as in vitro model systems.
  • Genetically modified cell lines expressed up to 1,800 times more hTPO as compared to wild type tumour cells.
  • The transduction of the hTPO gene per se is not sufficient to restore iodide trapping in non-iodide-concentrating tumour cells.
  • [MeSH-major] Carcinoma / metabolism. Iodide Peroxidase / genetics. Iodine / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Animals. Drug Resistance / genetics. Genetic Vectors. Humans. Iodine Radioisotopes / therapeutic use. Liver Neoplasms, Experimental / metabolism. Neomycin / pharmacology. Rats. Retroviridae. Thyroglobulin / metabolism. Transfection. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. NEOMYCIN .
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11383870.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 1404-04-2 / Neomycin; 9010-34-8 / Thyroglobulin; 9679TC07X4 / Iodine; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


34. Lu TX, Mai WY, Teh BS, Hu YH, Lu HH, Chiu JK, Carpenter LS, Woo SY, Butler EB: Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):589-98
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy.
  • PURPOSE: To evaluate the long-term outcome and prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after initial radiotherapy (RT).
  • METHODS AND MATERIALS: From January 1985 to December 1986, 100 patients (71 males, 29 females) with a diagnosis of nasopharyngeal carcinoma were found on computed tomography (CT) to have skull base erosion.
  • Ninety-six patients had World Health Organization type III undifferentiated carcinoma, and 4 had type I.
  • The metastatic workup, including chest radiography, liver ultrasound scanning, and liver function test was negative.
  • All patients underwent external beam RT (EBRT) alone to 66-80 Gy during 6-8 weeks.
  • A daily fraction size of 2 Gy was delivered using 60Co or a linear accelerator.
  • No patient received chemotherapy.
  • A difference in the time course of local recurrence and distant metastasis was observed.
  • CONCLUSIONS: We present one of the longest follow-ups of patients with nasopharyngeal carcinoma invading the skull base.
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Proportional Hazards Models. Skull Base / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597797.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tannuri AC, Tannuri U, Gibelli NE, Romão RL: Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation. J Pediatr Surg; 2009 Nov;44(11):2083-7
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of hepatic tumors in children: lessons learned from liver transplantation.
  • The objective of the present study was to describe our experience in liver resections, in the light of liver transplantation, emphasizing the indications for surgery, surgical techniques, complications, and results.
  • METHODS: The medical records of 53 children who underwent liver resection for primary or metastatic hepatic tumors were reviewed.
  • After neoadjuvant chemotherapy, tumor resectability was evaluated by another CT scan.
  • Surgery was performed by surgeons competent in liver transplantation.
  • As in liver living donor operation, vascular anomalies were investigated.
  • Hilar structures were dissected very close to liver parenchyma.
  • The hepatic artery and portal vein were dissected and ligated near their entrance to the liver parenchyma to avoid damaging the hilar vessels of the other lobe.
  • RESULTS: Fifty-three children with hepatic tumors underwent surgical treatment, 47 patients underwent liver resections, and in 6 cases, liver transplantation was performed because the tumor was considered unresectable.
  • Ten children presented with other malignant tumors-3 undifferentiated sarcomas, 2 hepatocellular carcinomas, 2 fibrolamellar hepatocellular carcinomas, a rhabdomyosarcoma, an immature ovarian teratoma, and a single neuroblastoma.
  • CONCLUSION: The resection of hepatic tumors in children requires expertise in pediatric surgical practice, and many lessons learned from liver transplantation can be applied to hepatectomies.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Age Factors. Blood Loss, Surgical. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Follow-Up Studies. Hepatectomy / methods. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Infant. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944212.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N: Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev; 2008 Dec;34(8):693-700
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.
  • AIM: Patients with liver metastases from cancer of unknown primary (CUPL) have a dismal prognosis.
  • RESULTS: All our patients (males: 31, females: 18; median age: 65) underwent a computed tomography scan (CT) of the abdomen, 71% a thoracic CT, 53% gastroscopy and 47% colonoscopy.
  • The commonest histologic subtypes encountered were adenocarcinoma (N=34) or undifferentiated carcinoma (N=12).
  • The liver was the only metastatic site in 38% of patients, while it was accompanied with other metastatic sites in 62% (the commonest: lung, bone and lymph nodes).
  • Forty-seven patients received first-line chemotherapy (42 platinum based) and 16 second-line.
  • CONCLUSIONS: Patients with liver metastases from CUP are resistant to conventional types of treatment and carry a poor prognosis.
  • Understanding the molecular biology of CUP is essential for the development of new, targeted effective therapies.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Biopsy, Needle. Female. Humans. Immunohistochemistry. Logistic Models. Lymph Nodes / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584969.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 22
  •  go-up   go-down


37. McCulley TJ, Yip CC, Bullock JD, Warwar RE, Hood DL: Cervical carcinoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2002 Sep;18(5):385-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical carcinoma metastatic to the orbit.
  • PURPOSE: To describe a case of orbital metastasis from an undifferentiated pelvic tumor with probable cervical origination.
  • Diplopia in downgaze developed shortly after hospitalization.
  • On metastatic workup, lesions were found involving the left femoral head, liver, and spinal column, with adjacent lymphadenopathy.
  • Despite treatment with radiation and chemotherapy, the patient died several months later of causes related to the systemic disease.
  • [MeSH-major] Carcinoma / secondary. Orbital Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diplopia / etiology. Female. Humans. Tomography, X-Ray Computed


38. Czauderna P, Popadiuk S, Korzon M, Stoba C, Szymik-Kantorowicz S, Sawicz-Birkowska K, Lopatka B, Bogusławska-Jaworska J, Kowalczyk J, Sopyło B, Madziara W, Juszkiewicz P, Swiatkiewicz V, Skotnicka-Klonowicz G, Włodarczyk A: Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors--management in a series of 47 Polish patients (1985-1995). Eur J Pediatr Surg; 2001 Apr;11(2):82-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter retrospective analysis of various primary pediatric malignant hepatic tumors--management in a series of 47 Polish patients (1985-1995).
  • Forty-seven children treated in various Polish centers between 1985 and 1995 for primary malignant liver tumors were retrospectively analyzed.
  • There were 6 hepatocarcinoma (HCC) cases and 2 cases of undifferentiated sarcoma (UDS).
  • In 44% of HB patients the tumor involved both liver lobes.
  • 18% of children with HB presented with pulmonary metastases at diagnosis.
  • Chemotherapy was applied in 92% of cases (preoperatively in 67%).
  • Overall survival of patients with hepatoblastoma was 43.6%, while it was 50% for hepatocarcinoma and 100% for undifferentiated sarcoma (2 cases only).
  • Mean observation time was 58 months.
  • Involvement of both lobes of the liver and multifocality of the tumor were other adverse prognostic factors.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatoblastoma / surgery. Liver Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Poland / epidemiology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371041.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Parker LP, Duong JL, Wharton JT, Malpica A, Silva EG, Deavers MT: Desmoplastic small round cell tumor: report of a case presenting as a primary ovarian neoplasm. Eur J Gynaecol Oncol; 2002;23(3):199-202
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor: report of a case presenting as a primary ovarian neoplasm.
  • BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is an intra-abdominal malignancy that typically has extensive peritoneal spread at the time of diagnosis.
  • During tumor reductive surgery the right ovary, omentum, and liver were found to be involved.
  • Initial histologic examination favored an undifferentiated small cell carcinoma of the ovary.
  • The patient received two cycles of Taxol and cisplatin chemotherapy and was referred to the University of Texas M. D.
  • Upon review of the pathology material at the time of the referral, a diagnosis of DSRCT was made.
  • Despite two additional cycles of chemotherapy, the tumor progressed, and the patient returned home.
  • CONCLUSION: DSRCT may mimic an ovarian primary tumor by presenting with involvement of the ovary and an elevated CA-125 level, and should be included in the differential diagnosis of ovarian neoplasms in young patients.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Liver Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CA-125 Antigen / blood. Cisplatin / administration & dosage. Diagnosis, Differential. Female. Humans. Omentum / pathology. Paclitaxel / administration & dosage


40. Petraki C, Vaslamatzis M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, Gregorakis A: Prostate cancer with small-cell morphology: an immunophenotypic subdivision. Scand J Urol Nephrol; 2005;39(6):455-63
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the immunophenotypic characteristics and clinical outcome of morphologically undifferentiated prostatic carcinoma with small-cell morphology (U-PC-SCM).
  • The streptavidin-biotin complex immunohistochemical method was used on paraffin-embedded tissue sections to test positivity for prostate-specific antigen, prostate-specific acid phosphatase, CD57, androgen receptors, CK8-18, epithelial membrane antigen, carcinoembryonic antigen, CD56, neuron-specific enolase, chromogranin, synaptophysin, serotonin, various hormones, thyroid transcriptional factor-1 and Ki-67/MIB1.
  • The final diagnosis was U-PC (Gleason score 10) in Group 1 (n=9) and pure or mixed neuroendocrine small-cell carcinoma in Group 2 (n=7).
  • The third patient showed a partial response (PR) for 18 months but eventually relapsed with liver metastatic lesions.
  • He was then treated with cisplatin + etoposide and showed a PR for 3 months and survived for 5 months after the initiation of the second-line chemotherapy (CTH) treatment.
  • [MeSH-major] Biomarkers, Tumor / immunology. Carcinoma, Small Cell / immunology. Immunophenotyping. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303720.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


43. Torrejón Reyes PN, Frisancho O, Gómez A, Yábar A: [Malignant peritoneal mesothelioma]. Rev Gastroenterol Peru; 2010 Jan-Mar;30(1):82-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis.
  • We report a case of a 58 year old man with diabetes mellitus type 2, arterial hypertension and smoking; without precedent of asbestos exposure.
  • The abdomen distended by ascites, not painful, liver and spleen not examined.
  • Cytology: mesothelial cells with changes of type reagent, Block cell for tumour cells: negative.
  • The report of the peritoneal biopsy was informed as suggestive of undifferentiated carcinoma; the reappraisal with inmunohystochemic (calretinin +,cytokeratin +, vimentin +) indicated malignant peritoneal mesothelioma, type epithelial.
  • The patient was transferred to the Service of Oncology where they initiated chemotherapy with Cysplatin (CDDP) and died 20 days later.
  • The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445731.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


44. Liu JJ, Wang JY, Hertervig E, Nilsson A, Duan RD: Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells. Anticancer Res; 2002 Jan-Feb;22(1A):263-6
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has recently been reported that sulindac has an apoptotic effect on KYN-2 cells, an undifferentiated hepatoma cell line.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Carcinoma, Hepatocellular / drug therapy. Caspases / metabolism. Liver Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Caspase 3. Cell Division / drug effects. DNA, Neoplasm / antagonists & inhibitors. DNA, Neoplasm / biosynthesis. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Humans. Sphingomyelin Phosphodiesterase / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12017300.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; K619IIG2R9 / sulindac sulfone
  •  go-up   go-down






Advertisement